743002
Last Update Posted: 2013-06-21
Recruiting has ended
All Genders accepted | 18 Years-75 Years |
87 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
Eligibility
Relevant conditions:
Diabetes Mellitus, Type 2
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov